Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

11.6%

11 terminated/withdrawn out of 95 trials

Success Rate

77.6%

-9.0% vs industry average

Late-Stage Pipeline

15%

14 trials in Phase 3/4

Results Transparency

18%

7 of 38 completed trials have results

Key Signals

18 recruiting7 with results10 terminated

Enrollment Performance

Analytics

Phase 2

45(71.4%)

Phase 3

14(22.2%)

N/A

2(3.2%)

Phase 1

2(3.2%)

63Total

Phase 2(45)

Phase 3(14)

N/A(2)

Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (95)

Showing 20 of 95 trials

NCT07453095Phase 2Not Yet Recruiting

Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy

Role: lead

NCT07476105Not ApplicableNot Yet Recruiting

Geriatric-guided Care Versus Conventional Care in Elderly Unfit/Frail Patients With Diffuse Large B-cell Lymphoma in First Line Treatment

Role: lead

NCT07467317Not Yet Recruiting

BV-CHP Real-life and Biological Evidences in Patients With sALCL

Role: lead

NCT07463781Not Yet Recruiting

Neurocognitive Assessment in Adults Undergoing CD19 Targeted CAR-T Cell Therapy

Role: lead

NCT05300282Phase 1Recruiting

Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients

Role: lead

NCT06492837Phase 2Recruiting

Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients

Role: lead

NCT05524298Recruiting

Quality Of Life On Elderly Patients With Low Grade Non-Hodgkin Lymphoma

Role: lead

NCT05934084Not ApplicableRecruiting

Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors

Role: lead

NCT05819528Recruiting

Primary Cardiac Lymphoma: Italian Multicenter Experience

Role: lead

NCT06441214Active Not Recruiting

Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval.

Role: lead

NCT04882475Active Not Recruiting

Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.

Role: lead

NCT05249959Phase 2Recruiting

Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.

Role: lead

NCT06835530Phase 2Recruiting

A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)

Role: lead

NCT06008691Recruiting

A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice

Role: lead

NCT05816850Recruiting

Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial

Role: lead

NCT06588205Recruiting

Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma

Role: lead

NCT05929222Phase 3Recruiting

Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi

Role: lead

NCT04915248Phase 2Recruiting

Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.

Role: lead

NCT03731234Phase 2Active Not Recruiting

Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance

Role: lead

NCT05162170Completed

Primary Mediastinal Large B-cell Lymphoma (PMBCL): Multicenter Retrospective Study

Role: lead